Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18984062 | METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER | December 2024 | September 2025 | Allow | 9 | 1 | 0 | No | No |
| 18743624 | GENE THERAPY FOR NEURODEGENERATIVE DISORDERS | June 2024 | January 2026 | Abandon | 19 | 0 | 1 | No | No |
| 18649453 | MARKER FOR ACID SPHINGOMYELINASE DISORDERS AND USES THEREOF | April 2024 | November 2025 | Allow | 19 | 1 | 0 | No | No |
| 18645977 | PROTEIN BIOMARKER INDICATORS OF NEUROLOGICAL INJURY AND/OR DISEASE AND METHODS OF USE THEREOF | April 2024 | January 2026 | Allow | 21 | 1 | 1 | Yes | No |
| 18637770 | BIOMARKER DETECTION PROCESS AND ASSAY OF NEUROLOGICAL CONDITION | April 2024 | December 2025 | Allow | 20 | 1 | 0 | No | No |
| 18604668 | ANTIBODIES TO AMYLOID BETA | March 2024 | February 2025 | Allow | 11 | 0 | 0 | No | No |
| 18603889 | METHOD OF DETERMINING TOXICITY OF AN IMMUNOMODULATORY DRUG FOR USE IN HUMANS | March 2024 | August 2025 | Allow | 17 | 1 | 1 | Yes | No |
| 18443416 | USE OF ONE OR MORE BIOMARKERS TO DETERMINE TRAUMATIC BRAIN INJURY (TBI) IN A HUMAN SUBJECT HAVING RECEIVED A HEAD COMPUTERIZED TOMOGRAPHY SCAN THAT IS NEGATIVE FOR A TBI | February 2024 | December 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18526952 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES | December 2023 | June 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18507265 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY INTRANASAL ADMINISTRATION OF IMMUNOGLOBULIN G | November 2023 | August 2025 | Allow | 21 | 1 | 0 | No | No |
| 18506582 | CHEMICAL REPROGRAMMING OF HUMAN GLIAL CELLS INTO NEURONS FOR BRAIN AND SPINAL CORD REPAIR | November 2023 | July 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18490689 | METHODS FOR TREATING SYSTEMIC SCLEROSIS | October 2023 | July 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18370557 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING AUTISM | September 2023 | December 2025 | Abandon | 26 | 1 | 1 | No | No |
| 18243915 | SENSE INDICATOR COMPOSITION | September 2023 | March 2025 | Abandon | 19 | 2 | 1 | No | No |
| 18453286 | BIOMARKERS AND METHODS OF USE FOR RADIATION-INDUCED LUNG INJURY | August 2023 | November 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18449971 | METHODS FOR EFFICIENT GENERATION OF GABAergic INTERNEURONS FROM PLURIPOTENT STEM CELLS | August 2023 | November 2024 | Allow | 15 | 1 | 0 | No | No |
| 18363113 | ANTIBODY WHICH BINDS TO MYELIN OLIGODENDROCYTE GLYCOPROTEIN | August 2023 | January 2025 | Allow | 17 | 0 | 0 | No | No |
| 18221053 | BIOMARKERS FOR COGNITIVE DYSFUNCTION DISEASES AND METHOD FOR DETECTING COGNITIVE DYSFUNCTION DISEASE USING BIOMARKERS | July 2023 | April 2025 | Allow | 21 | 3 | 0 | Yes | No |
| 18329892 | BIOMARKER LEVELS AND NEUROIMAGING FOR DETECTING, MONITORING AND TREATING BRAIN INJURY OR TRAUMA | June 2023 | July 2025 | Allow | 25 | 2 | 1 | Yes | No |
| 18135543 | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS | April 2023 | July 2025 | Abandon | 27 | 3 | 1 | No | No |
| 18190416 | METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER | March 2023 | September 2024 | Allow | 18 | 2 | 0 | No | No |
| 18121626 | COMPOSITION AND METHOD FOR TREATMENT OF NEUROPSYCHIATRIC DISORDERS | March 2023 | January 2025 | Allow | 22 | 1 | 0 | No | No |
| 18160624 | COMPOSITIONS AND METHODS FOR A UNIVERSAL CLINICAL TEST FOR OLFACTORY DYSFUNCTION | January 2023 | March 2025 | Allow | 26 | 1 | 1 | No | No |
| 18146791 | Novel Therapeutic Uses of Mu-Opiate Receptor Peptides | December 2022 | November 2024 | Abandon | 22 | 0 | 1 | No | No |
| 18077711 | DETECTION OF PHOSPHOINOSITIDES IN BLOOD CELLS AS A BIOMARKER FOR ALPHA SYNUCLEIN ASSOCIATED PATHOLOGIES AND A METHOD OF TREATMENT OF PARKINSON'S DISEASE AND THE RELATED NEURODEGENERATIONS | December 2022 | February 2026 | Abandon | 38 | 0 | 1 | No | No |
| 17925160 | MEANS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL AGGREGATION | November 2022 | January 2026 | Abandon | 38 | 0 | 1 | No | No |
| 17924214 | FORMULATION COMPRISING ANTI-IL-23P19 ANTIBODY, METHOD FOR PREPARING SAME AND USE THEREOF | November 2022 | January 2026 | Allow | 38 | 1 | 0 | No | No |
| 17968606 | Detection of Structural Forms of Proteins | October 2022 | August 2025 | Abandon | 34 | 2 | 1 | No | No |
| 17918860 | FELINE ANTIBODY VARIANTS | October 2022 | February 2026 | Allow | 40 | 1 | 0 | No | No |
| 17937529 | USE OF FcgammaRIII INHIBITOR IN PREPARATION OF MEDICAMENT FOR TREATING PULMONARY FIBROSIS | October 2022 | February 2026 | Allow | 41 | 1 | 0 | No | No |
| 17937109 | TAU IMMUNOTHERAPY | September 2022 | September 2024 | Allow | 23 | 2 | 0 | Yes | No |
| 17915334 | AGENTS FOR USE IN THE THERAPEUTIC OR PROPHYLACTIC TREATMENT OF RETINAL PIGMENT EPITHELIUM ASSOCIATED DISEASES | September 2022 | December 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17915153 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | September 2022 | March 2026 | Abandon | 42 | 1 | 1 | No | No |
| 17914101 | Type XIX Collagen Assay | September 2022 | January 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17893019 | USE OF PAK4 AND CRTC1 FOR TREATMENT OR DIAGNOSIS OF BRAIN DEGENERATIVE DISEASE | August 2022 | December 2025 | Allow | 40 | 1 | 0 | No | No |
| 17812678 | Determining WT-1-Specific T Cells and WT-1 Specific T Cell Receptors (TCRS) | July 2022 | January 2026 | Allow | 43 | 0 | 1 | No | No |
| 17784417 | IMMUNOASSAY METHOD AND IMMUNOASSAY APPARATUS | June 2022 | November 2025 | Allow | 42 | 1 | 0 | No | No |
| 17782468 | Neo-Epitope Specific Assay Measuring Protease Mediated Degradation of Type IV Collagen | June 2022 | October 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17824980 | COMPOSITIONS AND METHODS FOR IDENTIFYING MHC-II BINDING PEPTIDES | May 2022 | November 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17778738 | COMPOSITIONS AND METHODS FOR DEREPRESSING RE1 SILENCING TRANSCRIPTION FACTOR TARGET GENES | May 2022 | September 2024 | Allow | 28 | 1 | 1 | Yes | No |
| 17748943 | LITHIUM AS A MONOTHERAPY AND/OR STEM CELL ADJUVANT THERAPY FOR PULMONARY FIBROSIS | May 2022 | December 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17743288 | CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY | May 2022 | March 2025 | Allow | 34 | 2 | 1 | No | No |
| 17739912 | Methods For The Treatment Of Neurodegeneration | May 2022 | August 2024 | Allow | 28 | 1 | 0 | No | No |
| 17719243 | DETECTION OF DEBRIS IN RECIRCULATING PHAGOCYTES | April 2022 | December 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17765466 | NOVEL FLUORESCENT PROTEIN AND UTILIZATION THEREOF | March 2022 | September 2025 | Allow | 41 | 1 | 0 | No | No |
| 17671430 | ASSEMBLY OF FUNCTIONALLY INTEGRATED HUMAN FOREBRAIN SPHEROIDS AND METHODS OF USE THEREOF | February 2022 | August 2024 | Allow | 30 | 2 | 0 | Yes | No |
| 17630880 | CULTURE MEDIUM FOR HAEMATOPOIETIC INDUCTION | January 2022 | October 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17580689 | INHIBITION OF LET7I AS A MEANS TO ENHANCE THE PROTECTIVE EFFECT OF PROGESTERONE AGAINST STROKE | January 2022 | December 2024 | Abandon | 35 | 2 | 0 | No | No |
| 17625434 | METHOD AND COMPOSITION FOR TREATING PAIN | January 2022 | March 2026 | Allow | 50 | 2 | 1 | Yes | No |
| 17617048 | METHODS AND COMPOSITIONS FOR DIFFERENTIATING STEM CELLS | December 2021 | February 2026 | Abandon | 50 | 1 | 1 | No | No |
| 17616031 | ANTI-OPIOID COMPOUNDS AND METHODS OF MAKING AND USING SAME | December 2021 | December 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17605327 | CANCER DETECTION METHOD AND DETECTION REAGENT | October 2021 | May 2025 | Abandon | 43 | 2 | 1 | Yes | No |
| 17600728 | METHOD FOR DETECTING OR MONITORING THE DEVELOPMENT OF A CHRONIC PROLIFERATIVE DISEASE BY IMMUNOASSAY | October 2021 | June 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17441010 | Patient Populations Amenable to IL23-Antagonist Therapy | September 2021 | June 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17411787 | DECELLULARIZED NERVE ALLOGRAFTS | August 2021 | June 2025 | Abandon | 46 | 2 | 1 | No | No |
| 17433970 | LIVE CELL IMAGING DYNAMIC BH3 PROFILING | August 2021 | September 2025 | Allow | 49 | 2 | 0 | No | No |
| 17406051 | RECOMBINANT CLUSTERIN AND USE THEREOF IN THE TREATMENT AND PREVENTION OF DISEASE | August 2021 | January 2025 | Abandon | 41 | 2 | 0 | No | No |
| 17402986 | ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF | August 2021 | June 2024 | Allow | 34 | 0 | 0 | Yes | No |
| 17429046 | Type XXIII Collagen Assay | August 2021 | April 2025 | Allow | 44 | 1 | 0 | No | No |
| 17428567 | TREATMENT OF CANCER METASTASIS BY TARGETING EXOSOME PROTEINS | August 2021 | October 2025 | Allow | 50 | 1 | 1 | No | No |
| 17427698 | METHOD FOR TREATING CHECKPOINT INHIBITORS INDUCED ADVERSE EVENTS | August 2021 | December 2025 | Allow | 53 | 3 | 0 | No | No |
| 17380704 | Compositions and Methods for Modulating Kinase Activity | July 2021 | December 2024 | Allow | 40 | 2 | 0 | No | No |
| 17421874 | MULTI-TARGETING FUSION PROTEIN FOR BLOCKING THE GROWTH OF VASCULAR ENDOTHELIAL CELLS AND ACTIVATING T CELLS AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | July 2021 | November 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17362126 | ANTI-RABBIT CD19 ANTIBODIES AND METHODS OF USE | June 2021 | March 2025 | Allow | 45 | 1 | 1 | No | No |
| 17345451 | Microfluidic Device For Cell Separation And Uses Thereof | June 2021 | January 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17298234 | CANCER DETECTION UTILIZING NORMAL TISSUE ADJACENT TO BREAST TUMORS WITH GENETIC ANCESTRY-MAPPING | May 2021 | July 2025 | Abandon | 50 | 2 | 0 | No | No |
| 17313587 | THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS FOR NEURODEGENERATIVE DISEASES | May 2021 | August 2024 | Allow | 40 | 3 | 0 | No | No |
| 17274399 | METHOD FOR DIAGNOSING DEMENTIA OR DETERMINING THE RISK OF DEVELOPING DEMENTIA | March 2021 | March 2026 | Abandon | 60 | 4 | 1 | No | No |
| 17192679 | Compositions and Methods for Detecting and Treating Brain Injury Associated Fatigue and Altered Cognition (BIAFAC) | March 2021 | March 2025 | Abandon | 48 | 3 | 1 | No | No |
| 17264601 | COMBINED INVASION AND CYTOTOXICITY ASSAY USING CHEMOKINE SECRETING TARGET CELLS | January 2021 | August 2025 | Allow | 55 | 3 | 1 | Yes | No |
| 17146336 | METHOD AND COMPOSITION FOR GENERATING BASAL FOREBRAIN CHOLINERGIC NEURONS (BFCNs) | January 2021 | December 2024 | Abandon | 47 | 2 | 1 | No | No |
| 17255811 | SYNTHETIC ODORANT RECEPTORS | December 2020 | August 2024 | Allow | 43 | 3 | 1 | Yes | No |
| 17250209 | Sponge patch complex of stem cell preparation for treating brain diseases, preparation method thereof, and application thereof | December 2020 | January 2025 | Abandon | 49 | 1 | 1 | Yes | No |
| 17112570 | MHC CLASS II MOLECULE-BASED PEPTIDE EXCHANGE SYSTEM AND METHOD | December 2020 | May 2025 | Abandon | 54 | 2 | 1 | Yes | No |
| 16972015 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | December 2020 | December 2025 | Allow | 60 | 1 | 1 | Yes | No |
| 17108441 | CELL-BASED ZNT8 ASSAY | December 2020 | March 2025 | Allow | 51 | 2 | 0 | No | No |
| 17099209 | COMPOSITIONS AND METHODS FOR MODULATING NEURONAL EXCITABILITY AND MOTOR BEHAVIOR | November 2020 | August 2024 | Allow | 45 | 2 | 1 | No | No |
| 16766529 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE, AND CELL MASS THEREOF | May 2020 | July 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16876030 | Genome-Based Methods For Reducing Cardiovascular Risk | May 2020 | November 2024 | Allow | 54 | 3 | 1 | No | No |
| 16640907 | METHODS OF TREATING UREA CYCLE DISORDERS BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING | February 2020 | June 2024 | Allow | 52 | 2 | 1 | Yes | No |
| 16622891 | BIOMARKERS FOR WOUND HEALING | December 2019 | March 2026 | Allow | 60 | 3 | 1 | Yes | No |
| 16495131 | METHOD OF SCREENING FOR ANTI-DRUG ANTIBODIES AGAINST IMMUNOGLOBULIN SINGLE VARIABLE DOMAIN-BASED DRUGS | September 2019 | July 2025 | Allow | 60 | 7 | 0 | Yes | No |
| 16470537 | USE OF APOE4 MOTIF-MEDIATED GENES FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE | June 2019 | April 2025 | Allow | 60 | 7 | 1 | Yes | No |
| 16441902 | COMPOSITIONS, DEVICES, AND METHODS OF ATTENTION DEFICIT DISORDER/ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADD/ADHD) SENSITIVITY TESTING | June 2019 | June 2025 | Abandon | 60 | 5 | 1 | No | Yes |
| 16410763 | METHODS FOR DRUG DISCOVERY USING STEM CELL-DERIVED SCHWANN CELLS | May 2019 | April 2025 | Abandon | 60 | 6 | 2 | No | No |
| 16230216 | MAMMALIAN CELL CULTURE-PRODUCED NEUBLASTIN ANTIBODIES | December 2018 | January 2020 | Allow | 13 | 1 | 0 | No | No |
| 16304060 | METHOD FOR PRODUCING NEURAL STEM CELLS, MEDIUM, SUPPLEMENT, SUPPLEMENT SET, MEDIUM KIT, AND CELL CULTURE DEVICE | November 2018 | July 2024 | Allow | 60 | 7 | 1 | Yes | No |
| 15772515 | METHODS FOR APOLIPOPROTEIN DETECTION | September 2018 | February 2026 | Allow | 60 | 6 | 1 | Yes | No |
| 16015748 | CELL-BASED TREATMENT AND DRUG DISCOVERY IN HIRSCHSPRUNG'S DISEASE ENABLED BY PLURIPOTENT STEM CELL-DERIVED HUMAN ENTERIC NEURAL CREST LINEAGES | June 2018 | March 2025 | Allow | 60 | 8 | 1 | No | No |
| 15458185 | Neuromuscular Junction: NMJ-ON-CHIP | March 2017 | July 2025 | Abandon | 60 | 8 | 1 | No | No |
| 15504301 | METHODS TO ENHANCE NERVE REGENERATION UTILIZING NEURAL STEM CELLS AND IL12P40 | February 2017 | April 2019 | Allow | 26 | 2 | 1 | Yes | No |
| 15104149 | BIOMARKERS AND METHODS RELATING TO ALZHEIMER'S DISEASE | June 2016 | March 2025 | Allow | 60 | 8 | 2 | Yes | Yes |
| 14916602 | NAV1.7 ANTIBODIES AND METHODS OF USING THE SAME | March 2016 | September 2018 | Allow | 31 | 2 | 1 | No | No |
| 14894980 | SINGLE DOMAIN ANTIBODIES AGAINST SOD1 AND THEIR USE IN MEDICINE | November 2015 | September 2017 | Allow | 21 | 2 | 1 | Yes | No |
| 14782078 | METHOD FOR DETECTING ASYN-SPECIFIC ANTIBODIES IN A BIOLOGICAL SAMPLE | October 2015 | January 2018 | Allow | 27 | 2 | 1 | Yes | No |
| 14402145 | Method of Inhibiting C5a | November 2014 | February 2019 | Allow | 51 | 8 | 1 | Yes | No |
| 14334643 | METHODS FOR INHIBITING THE DEVELOPMENT OF HUNTINGTON'S DISEASE | July 2014 | March 2016 | Allow | 20 | 1 | 0 | No | No |
| 14288374 | ANTIBODIES AND THEIR USE IN THE TREATMENT, PREVENTION AND DIAGNOSIS OF A DISEASE ASSOCIATED WITH SOD1 ABNORMALITIES | May 2014 | October 2015 | Allow | 17 | 1 | 1 | Yes | No |
| 14068648 | METHOD OF TREATING STROKE COMPRISING ADMINISTERING METAL CHELATORS TO THE UPPER ONE-THIRD OF THE NASAL CAVITY | October 2013 | January 2016 | Allow | 27 | 1 | 0 | No | No |
| 14063125 | METHODS OF TREATING HUNTINGTON'S DISEASE COMPRISING ADMINISTERING METAL CHELATORS TO THE UPPER ONE-THIRD OF THE NASAL CAVITY | October 2013 | August 2015 | Allow | 21 | 1 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MACFARLANE, STACEY NEE.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 37.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner MACFARLANE, STACEY NEE works in Art Unit 1675 and has examined 153 patent applications in our dataset. With an allowance rate of 88.9%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 45 months.
Examiner MACFARLANE, STACEY NEE's allowance rate of 88.9% places them in the 70% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by MACFARLANE, STACEY NEE receive 2.82 office actions before reaching final disposition. This places the examiner in the 82% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by MACFARLANE, STACEY NEE is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +21.0% benefit to allowance rate for applications examined by MACFARLANE, STACEY NEE. This interview benefit is in the 65% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 26.6% of applications are subsequently allowed. This success rate is in the 44% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 48.9% of cases where such amendments are filed. This entry rate is in the 73% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 88.2% of appeals filed. This is in the 81% percentile among all examiners. Of these withdrawals, 86.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 56.5% are granted (fully or in part). This grant rate is in the 58% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 19.0% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.9% of allowed cases (in the 73% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.